339 related articles for article (PubMed ID: 34386017)
41. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
42. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Pagel JM; West HJ
JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
[No Abstract] [Full Text] [Related]
43. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
44. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
45. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
Bayón-Calderón F; Toribio ML; González-García S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
[TBL] [Abstract][Full Text] [Related]
46. Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
Mensali N; Myhre MR; Dillard P; Pollmann S; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Cancer Immunol Immunother; 2019 Aug; 68(8):1235-1243. PubMed ID: 31214732
[TBL] [Abstract][Full Text] [Related]
47. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.
Son J; George GC; Nardo M; Krause KJ; Jazaeri AA; Biter AB; Hong DS
Gynecol Oncol; 2022 Jun; 165(3):664-670. PubMed ID: 35400527
[TBL] [Abstract][Full Text] [Related]
48. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
Mayor P; Starbuck K; Zsiros E
Gynecol Oncol; 2018 Aug; 150(2):361-369. PubMed ID: 29803316
[TBL] [Abstract][Full Text] [Related]
49. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Huang D; Miller M; Ashok B; Jain S; Peppas NA
Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
[TBL] [Abstract][Full Text] [Related]
50. TCR Gene Therapy: Challenges, Opportunities, and Future Directions.
Stauss HJ; Tran MGB
Cells; 2020 Dec; 9(12):. PubMed ID: 33271744
[TBL] [Abstract][Full Text] [Related]
51. Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors.
Ochi T; Maruta M; Hirano N
Methods Mol Biol; 2019; 2048():27-39. PubMed ID: 31396926
[TBL] [Abstract][Full Text] [Related]
52. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
53. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
54. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
55. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.
Alcantara M; Tesio M; June CH; Houot R
Leukemia; 2018 Nov; 32(11):2307-2315. PubMed ID: 30315238
[TBL] [Abstract][Full Text] [Related]
56. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
57. CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer.
Nasiri F; Farrokhi K; Safarzadeh Kozani P; Mahboubi Kancha M; Dashti Shokoohi S; Safarzadeh Kozani P
Front Immunol; 2023; 14():1302307. PubMed ID: 38146364
[TBL] [Abstract][Full Text] [Related]
58. CAR T-cells for relapsed B-cell ALL in adults.
Gilbert JA
Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
[No Abstract] [Full Text] [Related]
59. Chimeric antigen receptor T cell therapies for multiple myeloma.
Wu C; Zhang L; Brockman QR; Zhan F; Chen L
J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
[TBL] [Abstract][Full Text] [Related]
60. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
